Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 14Genitourinary 3Sarcoma 2

Conditions

Sarcoma 286Gliosarcoma 149Glioblastoma 149Brain Neoplasms 90Osteosarcoma 84Glioma 68Gastrointestinal Stromal Tumors 68Rhabdomyosarcoma 65Lymphoma, Non-Hodgkin 59Astrocytoma 59Recurrence 57Dendritic Cell Sarcoma, Interdigitating 57Sarcoma, Ewing 55Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Lymphoma 50Burkitt Lymphoma 49Central Nervous System Neoplasms 48Neuroblastoma 47Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Follicular 46Neoplasm Metastasis 45Lymphoma, Mantle-Cell 45Leiomyosarcoma 44Oligodendroglioma 43Leukemia, Myeloid, Acute 43Liposarcoma 42Lymphoma, B-Cell, Marginal Zone 41Leukemia, Lymphocytic, Chronic, B-Cell 41Hodgkin Disease 41

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT00478426 2020-02-17

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
34 enrolled 10 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡